

# Glycosylation defects: a new mechanism for muscular dystrophy?

Prabhjit K. Grewal<sup>†</sup> and Jane E. Hewitt\*

Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK

Received July 2, 2003; Accepted July 18, 2003

Recently, post-translational modification of proteins has been defined as a new area of focus for muscular dystrophy research by the identification of a group of disease genes that encode known or putative glycosylation enzymes. Walker–Warburg Syndrome (WWS) and muscle–eye–brain disease (MEB) are caused by mutations in two genes involved in *O*-mannosylation, *POMT1* and *POMGnT1*, respectively. Fukuyama muscular dystrophy (FCMD) is due to mutations in *fukutin*, a putative phospholigand transferase. Congenital muscular dystrophy type 1C and limb girdle muscular dystrophy type 2I are allelic, both being due to mutations in the gene-encoding fukutin-related protein (*FKRP*). Finally, the causative gene in the myodystrophy (*myd*) mouse is a putative bifunctional glycosyltransferase (Large). WWS, MEB, FCMD and the *myd* mouse are also associated with neuronal migration abnormalities (often type II lissencephaly) and ocular or retinal defects. A deficiency in post-translational modification of  $\alpha$ -dystroglycan is a common feature of all these muscular dystrophies and is thought to involve *O*-glycosylation pathways. This abnormally modified  $\alpha$ -dystroglycan is deficient in binding to extracellular matrix ligands, including laminin and agrin. Selective deletion of dystroglycan in the central nervous system (CNS) produces brain abnormalities with striking similarities to WWS, MEB, FCMD and the *myd* mouse. Thus, impaired dystroglycan function is strongly implicated in these diseases. However, it is unlikely that these five glycosylation enzymes only have a role in glycosylation of  $\alpha$ -dystroglycan and it is important that other protein targets are identified.

## INTRODUCTION

The isolation of dystrophin and subsequent advances in identification of the interacting proteins that form the dystrophin-associated glycoprotein complex (DGC) led to an explosion in characterization of the muscular dystrophies (1–5). Recently, the focus has shifted to post-translational modifications of proteins as genes encoding proteins involved in glycosylation have defined a new area of attention in muscular dystrophy research. As well as giving further insights into mechanisms underlying muscular dystrophy, study of these diseases may increase our understanding of the functions of protein glycosylation. Although the function of most glycosylation is poorly understood, many vertebrate proteins are post-translationally modified by carbohydrates and it has been estimated that 1% of human genes encode enzymes involved in oligosaccharide synthesis and function (6).

These types of muscular dystrophy appear to be distinct from the congenital disorders of glycosylation (CDGs), a group of

diseases caused by defects in the well-characterized and highly conserved *N*-glycosylation pathways (7). Many CDGs are multisystemic due to defects in the modification of a wide range of proteins. In contrast, the glycosylation-deficient muscular dystrophies appear to involve the less well-defined *O*-glycosylation pathways and defective post-translation modification seems to be confined to a small number of proteins (of which only one has so far been identified; dystroglycan). In this review, we focus on those genes whose mutation appears to disrupt the function of the DGC.

## GLYCOSYLATION GENES ASSOCIATED WITH INHERITED MUSCULAR DYSTROPHIES

### *POMT1*

*POMT1* is the human homologue of the *Drosophila* *rotated abdomen* (*rt*) gene (8). The human gene is widely expressed

\*To whom correspondence should be addressed at: Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. Tel: +44 1158493229; Fax: +44 1159709906; Email: jane.hewitt@nottingham.ac.uk

<sup>†</sup>Present address:

Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California San Diego, California 92093, USA.

and encodes a predicted transmembrane protein with high homology to the yeast mannosyltransferases, suggesting a function in the first step in *O*-mannosylation of proteins. *O*-mannosylation is rare in mammals and has only been identified in a limited number of glycoproteins in brain, nerve and skeletal muscle (9). Homozygous *rt Drosophila* have abnormal embryonic muscle development (10), and Jurado *et al.* were the first to suggest that glycosylation might be important in the formation or maintenance of muscle (8). Mutations in *POMT1* cause Walker–Warburg Syndrome (WWS, MIM:236670), a very severe, recessive form of congenital muscular dystrophy (CMD) (11). Walker–Warburg Syndrome patients also have ocular and retinal abnormalities and brain defects including type II lissencephaly (12,13).

WWS is genetically heterogeneous as only about 20% of patients have point mutations in *POMT1* (14). Another candidate gene is *POMT2*, which encodes a closely related protein (15). However, *POMT2* is expressed at very low levels in skeletal muscle (15). Two WWS patients have recently been described with mutations in *fukutin* (see below), highlighting the clinical overlap of some of these diseases.

Although it is likely that both *POMT1* and *POMT2* encode mannosyltransferases, this catalytic activity has not yet been proven. Epitope-tagged *POMT2* localizes to the endoplasmic reticulum membrane (15). Although *in vitro* assays failed to demonstrate an *O*-mannosyl transfer reaction for either *POMT1* or *POMT2*, this is likely to be due to technical difficulties (15).

### **POMGnT1**

*POMGnT1* encodes the protein *O*-linked mannose  $\beta$ 1,2-*N*-acetylglucosaminyltransferase 1 (16,17). Mutations in *POMGnT1* have been described in muscle–eye–brain disease (MEB, MIM:253280), an autosomal recessive disorder characterized by congenital muscular dystrophy, brain malformations and ocular abnormalities (16,18). *POMGnT1* catalyzes the transfer of *N*-acetylglucosamine from UDP-GlcNAc to *O*-mannosyl glycoproteins (16,17,19). Mutations in MEB produce proteins that are nonfunctional when assayed *in vitro* (16). This is the strongest evidence in support of *O*-mannosylation defects in these muscular dystrophies and the similarity between the phenotypes of WWS and MEB is consistent with *POMT1* acting as an *O*-mannosyl transferase.

### **Fukutin**

Fukutin mutations are associated with Fukuyama congenital muscular dystrophy (FCMD, MIM:253800) (20,21). In addition to severe muscle weakness, there is also always severe mental retardation, with seizures occurring in about half the cases (21). The disease is most prevalent in Japan, where patients carry at least one copy of an ancestral founder mutation (integration of a 3 kb retrotransposon element into the 3' UTR) that results in a reduction in *fukutin* mRNA levels (21). Individuals who are homozygous for the founder mutation are less severely affected than compound heterozygotes with a point mutation on the other allele, presumably because they have a higher residual activity of fukutin (21). Recently, two non-Japanese individuals homozygous for truncating mutations have been reported with a WWS-type phenotype rather than

FCMD (14,22). Clinically, it can be difficult to differentiate between severe FCMD and mild WWS cases (23) and this genetic overlap implicates a function for fukutin in the same pathway as *POMT1*.

Null mouse mutants of *fukutin* are embryonic lethal. However, fukutin-deficient chimeric mice generated using embryonic stem (ES) cells targeted for both *fukutin* alleles have a phenotype that resembles WWS (24). The mice have a severe muscular dystrophy and neuronal migration defects, including disorganized laminar structures and fusion of medial surfaces of the cerebral cortex. Striking ocular abnormalities include abnormal lens development and loss of laminar structure in the retina.

The primary sequence of fukutin shows similarity to microbial proteins involved in polysaccharide/phosphorylcholine modification and mannosyl phosphorylation (25). The protein contains an N-terminal hydrophobic signal sequence but lacks a transmembrane domain and was initially suggested to be an extracellular protein (20). However, epitope-tagged protein has recently been reported to localize to the medial Golgi (20,26). No biochemical activity has yet been reported.

### **Fukutin-related protein (FKRP)**

The gene for FKRP was cloned on the basis of homology to the putative catalytic domain of fukutin (27). Mutations in this gene were identified in a subgroup of CMD patients (MDC1C, MIM:606612), with severe muscle weakness and inability to stand unsupported, but no evidence of brain involvement (27). Mutations in *FKRP* also account for the milder limb girdle muscular dystrophy type 2I (LGMD2I, MIM607155), therefore this disease is allelic with MDC1C (28). The spectrum of LGMD2I phenotypes is quite wide; a large proportion of patients share a common mutation (C826A; Leu276Ileu) and phenotypic severity is often correlated with the second allelic mutation (29). Although initially *FKRP* mutations were not associated with brain abnormalities (27–30), mutations in *FKRP* have recently been described in two patients with a pattern of muscle involvement identical to MDC1C but including mental retardation and cerebellar cysts (31).

FKRP is predicted to be a type II membrane protein and is targeted to the medial Golgi apparatus through its N-terminal and transmembrane domains (26). Overexpression of FKRP containing a missense mutation identified in MDC1C (P448L) caused the protein to be inefficiently trafficked to the Golgi apparatus (26). Although the function of the protein is unknown, like fukutin it is predicted to be a phospholigand transferase (27).

### **Large**

*Large* encodes a putative, bifunctional glycosyltransferase (32,33). A loss of function mutation is responsible for the myodystrophy (*myd*) mouse (34). Although initial investigations of the *myd* phenotype highlighted the skeletal muscle aspect of the disease (35,36), we and others have shown that the heart, retinal, peripheral and central nervous systems are also involved (37–39). Homozygous *myd* mice display a severe, progressive muscular dystrophy and a mild cardiomyopathy. Neuronal migration abnormalities are present in the brain,

particularly the cortex and cerebellum (38,39). These resemble the brain abnormalities observed in fukutin-deficient mice (24). Although morphologically the eyes and retina appear normal, electroretinograms showed a normal a-wave but increased implicit times and decreased amplitudes of the b-wave, suggesting altered signal processing in the downstream retinal circuitry (38).

Large has an N-terminal transmembrane anchor, typical of glycosyltransferases. It also has a coiled coil motif and two putative catalytic regions (32,34). The two catalytic domains are not closely related to each other, each showing homology to a different family of glycosyltransferases. The proximal domain is related to bacterial  $\alpha$ -glycosyltransferases involved in synthesis of lipopolysaccharides or lipooligosaccharides (40). The distal domain is most closely related to iGnT, required for synthesis of the poly-*N*-acetylglucosamine backbone ( $\text{Gal}\beta 1 \rightarrow 4\text{GlcNAc}\beta 1 \rightarrow 3$ )<sub>n</sub> found on *N*- and *O*-glycans and glycolipids (41).


## ABNORMAL GLYCOSYLATION OF DYSTROGLYCAN

The overlapping phenotypes of these muscular dystrophies suggest that the glycosylation proteins might act in a common pathway. Using immunoblot assays of total protein extracts, we observed a selective deficiency of  $\alpha$ -dystroglycan ( $\alpha$ -DG) in the *myd* mouse, which we speculated might reflect altered glycosylation of the protein (34). A deficiency in  $\alpha$ -DG is now known to be a common feature of all these glycosylation-deficient muscular dystrophies; in most cases this has been observed as a loss of immunoreactivity with one or both of the two commercially available monoclonal antibodies, VIA4-1 and IH6 (11,27,28,34,42,43).

More recently, an antibody to hypoglycosylated  $\alpha$ -DG generated by Kevin Campbell's group in Iowa was shown to identify a reduced molecular weight form of  $\alpha$ -DG in skeletal muscle from FCMD and WWS patients and from *myd* mice (39). Again, this was interpreted as hypoglycosylation  $\alpha$ -DG, although it is unclear why mutations in three different glycosylation enzymes should result in the same sized form of  $\alpha$ -DG. It is possible that aberrantly modified  $\alpha$ -DG is susceptible to proteolysis and the fragment is a common breakdown product.

### Dystroglycan function

Dystroglycan is a central component of the DGC in the sarcolemmal muscle membrane (Fig. 1). Its main function is in maintaining sarcolemmal integrity by linking cytoskeletal actin (via dystrophin) to components of the extracellular matrix (via  $\alpha$ -DG). Ligands for  $\alpha$ -DG include the laminin- $\alpha 1$  and - $\alpha 2$  chains, agrin, perlecan and neurexin (44,45). Mutations in almost all of the genes encoding components of the DGC or proteins that interact with the complex have been implicated in inherited forms of human muscular dystrophy or in animal models (1–5), although genetic forms of muscular dystrophy are not exclusively associated with the DGC (46). The complex is not confined to skeletal muscle, as some DGC components are associated with dystroglycan and dystrophin isoforms in



**Figure 1.** Schematic diagram of the skeletal muscle dystrophin-associated protein complex (DGC) (not drawn to scale). In skeletal muscle the DGC is composed of dystrophin, the dystroglycan complex of  $\alpha$ - and  $\beta$ -subunits, the sarcoglycans and sarcospan,  $\alpha$  and  $\beta 1$  syntrophins and dystrobrevin. *N*-glycosylation is indicated by purple circles, *O*-glycosylation by yellow circles. Up to one-half of the molecular mass of  $\alpha$ -dystroglycan is accounted for by carbohydrate. Mutations in genes encoding most of these components results in muscular dystrophy phenotypes in human and/or animal models. Laminins consist of heterotrimers of  $\alpha$ ,  $\beta$  and  $\gamma$  chains.  $\alpha$ -Dystroglycan binds to the laminin  $\alpha 2$  chain, the predominant  $\alpha$  chain in skeletal muscle, linking the DGC to the extracellular matrix. This binding requires carbohydrate structures on  $\alpha$ -dystroglycan, presumed to be part of the *O*-glycosylation.

other tissues including brain, peripheral nerve, retina and kidney (47–50).

Dystroglycan (*Dag1*) null mice are embryonic lethal due to very early defects in basement membrane assembly (51). Chimeric mice generated from *Dag1*<sup>-/-</sup> ES cells developed a progressive muscular dystrophy as the skeletal muscles lacked dystroglycan (52). Cre-LoxP technology has been used to produce conditional knockouts of dystroglycan. Loss of *Dag1* in differentiated skeletal muscle produced a relatively mild dystrophic phenotype as the satellite cells in this model are able to express dystroglycan successfully and regenerate muscle fibres (53). Elimination of dystroglycan from the CNS produced a phenotype with striking similarities to WWS, MEB, FCMD and the *myd* mouse with disruption of cortical layering, fusion of cerebral hemispheres and aberrant migration of granule cells (54). In combination with the evidence of altered glycosylation of  $\alpha$ -DG, this implicates an important role for dystroglycan in the muscle and brain phenotypes of the glycosylation-deficient muscular dystrophies.

### Dystroglycan glycosylation

Dystroglycan is post-translationally cleaved into  $\alpha$ - and  $\beta$ -subunits (55,56). The 43 kDa  $\beta$ -subunit, which is *N*-glycosylated, migrates at the expected mass in all the glycosylation-deficient muscular dystrophies, indicating that the precursor protein is synthesized and cleaved normally. In

the *myd* mouse, immunoblotting of muscle proteins treated with *N*-glycanases indicates that glycosylation of  $\beta$ -dystroglycan is not affected (unpublished data). Although it has a predicted weight of 72 kDa, on polyacrylamide gels  $\alpha$ -DG migrates as a heterogeneous band of much larger mass due to extensive glycosylation (55). The amount and type of protein glycosylation varies between tissues and developmental stages, with the apparent molecular mass varying between about 120 kDa in brain and peripheral nerve to >150 kDa in skeletal and cardiac muscle (44,57–59).

$\alpha$ -DG is modified by both *N*- and *O*-linked glycosylation (57). The protein is a dumbbell-shaped molecule with two globular domains separated by a central rod thought to be the *O*-glycosylated mucin-like domain (60). There is evidence for a requirement for sialylated *O*-glycans on  $\alpha$ -DG for binding to many of its ligands, including laminin, agrin, neurexin and perlecan (44,61). In MEB, FCMD and the *myd* mouse, binding of  $\alpha$ -DG to laminin, agrin and neurexin is defective (38,39). The monoclonal antibody I1H6, which recognizes a carbohydrate epitope on  $\alpha$ -DG, can block the interaction with laminin (58,62). The loss or reduction of binding by this antibody in conjunction with the predicted activities of POMT1 and POMGnT1, strongly suggests that defects in synthesis of *O*-linked sugars on  $\alpha$ -DG underlies the muscular dystrophy phenotypes described here. In addition, there is evidence (at least in *myd* mice) that *N*-glycosylation is not affected; mass spectrometry analysis of the profile of *N*-glycans showed no difference between the brains of *myd* and control mice (63). Furthermore, treatment of dystroglycan with *N*-glycanases does not alter its ligand binding activity, nor its immunoreactivity to the VIA4-1 and I1H6 monoclonal antibodies (58).

Several groups have isolated and sequenced glycans from purified  $\alpha$ -DG (reviewed and discussed in detail in ref. 64). Because this type of analysis requires significant amounts of protein as starting material, these studies have been carried out on sheep brain (65), cow peripheral nerve (66) and rabbit skeletal muscle (67). In each case, the same *O*-linked  $\alpha$ -mannose structure was identified (NeuAc $\alpha$ 2,3Gal $\beta$ 1,4GlcNAc $\beta$ 1,2Man $\alpha$ -Ser/Thr). Consequently, this structure has been the focus of much attention in recent literature, particularly as sialylated *O*-linked sugars have been implicated in the laminin-binding activity of dystroglycan (68). POMT1 is a good candidate for the initial attachment of the mannose to dystroglycan, while POMGnT1 is likely to add the GlcNAc residue (16,17). It has been suggested that fukutin, Large and FKRP function in the synthesis of this tetrasaccharide, although this is only conjecture. It should also be noted that not all the *O*-linked sugars on  $\alpha$ -DG are attached via mannose; a substantial proportion contain the more common structure Gal $\beta$ 1,3GalNAc-Ser/Thr (66,67).

## CONCLUSIONS AND PERSPECTIVES

### Phenotypic spectrum of glycosylation-deficient muscular dystrophies

Clinically, WWS, MEB and FCMD can be difficult to differentiate. In a screen of 30 patients diagnosed as WWS, severe FCMD or MEB, seven had mutations in *POMGnT1* (18). This highlights the need to consider all three genes when

screening for mutations in these diseases. Of the glycosylation genes identified thus far, mutations in *FKRP* are associated with the greatest phenotypic variation. However, this might not reflect any biological function but might be a consequence of screening a wider phenotypic spectrum of patients than for the other gene; the coding region of *FKRP* is contained within a single exon (27) simplifying mutation detection. The extensive amount of clinical and genotypic data accumulating for *FKRP* should prove useful in identifying functionally important regions of the protein and establishing genotype–phenotype correlations. For example, patients clinically diagnosed with MDC1C tend to carry two missense mutations or are compound heterozygotes for a nonsense and a missense mutation, while the common Leu276Ile changes are invariably associated with LGMD2I (29). The relatively mild nature of the *myd* phenotype (38) is quite surprising; it is possible that functional redundancy between Large and related glycosyltransferases can compensate in some tissues (33).

### Role for aberrant dystroglycan glycosylation in muscular dystrophy

Disruption of the laminin-binding activity of  $\alpha$ -DG, through aberrant glycosylation, seems a plausible mechanism for muscular dystrophy. Absence or abnormalities in laminins are associated with CMD phenotypes similar to those described here (69–71). Furthermore, the brain abnormalities in WWS, MEB, FCMD and *myd* reflect closely the effects of deletion of dystroglycan in the CNS (54). Although a direct action of POMT1 and POMGnT1 on dystroglycan *in vivo* has not been demonstrated, these enzymes are likely to be involved in the addition of *O*-mannosyl sugars to the protein. In mouse, dystroglycan, fukutin and POMGnT1 are co-expressed in late embryonic and early postnatal cerebellar neurons and glial cells (72). Co-expression of *FKRP* and dystroglycan in CHO cells alters the post-translational processing of  $\alpha$ -DG (26). However, it seems very unlikely that these five glycosylation enzymes identified so far each have the sole function of glycosylation of  $\alpha$ -DG. Different target specificities could account for differences in phenotypes between the diseases. For example, significant morphological ocular abnormalities are only associated with mutations in *POMT1*, *POMGnT1* and *fukutin*, suggesting that other targets for these enzymes play a role in normal eye development.

### Future perspectives

Important questions still to be addressed in this field include the definition of the biochemical activities of most of these enzymes. This will help to define the glycans required for  $\alpha$ -DG ligand interaction. Although technically difficult, glycan analysis of  $\alpha$ -DG from disease tissue to define the precise change in glycans would also be valuable in addressing this problem. As these muscular dystrophies are not due to structural abnormalities, potential therapeutic implications include enzyme replacement via gene therapy, upregulation of compensating glycosyltransferases or use of glycan analogues to restore laminin binding.

## ACKNOWLEDGEMENTS

The authors thank Chris Moore and Jenny McLaughlan for comments on the manuscript. Funding from The Wellcome Trust and The Muscular Dystrophy Association, USA, is gratefully acknowledged.

## NOTE ADDED IN PROOF

Since submission of this review, a case of muscular dystrophy associated with mutations in the human LARGE gene has been reported (F. Muntoni, personal communication).

## REFERENCES

- Durbeej, M. and Campbell, K.P. (2002) Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. *Curr. Opin. Gen. Dev.*, **12**, 349–361.
- Campbell, K.P. and Allmand, V. (2000) Animal models for muscular dystrophy: valuable tools for the development of therapies. *Hum. Mol. Genet.*, **9**, 2459–2467.
- Blake, D.J., Weir, A., Newey, S.E. and Davies, K.E. (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol. Rev.*, **82**, 291–329.
- Dalkilic, I. and Kunkel, L.M. (2003) Muscular dystrophies: genes to pathogenesis. *Curr. Opin. Gen. Dev.*, **13**, 231–238.
- Ervasti, J.M. (2003) Costameres: The Achilles' heel of herculean muscle. *J. Biol. Chem.*, **278**, 13591–13594.
- Lowe, J.B. and Marth, J.D. (2003) A genetic approach to mammalian glycan function. *Annu. Rev. Biochem.*, **72**, 643–691.
- Grünewald, S., Matthijs, G. and Jaeken, J. (2002) Congenital disorders of glycosylation: A review. *Pediatr. Res.*, **52**, 618–624.
- Jurado, L.A.P., Coloma, A. and Cruces, J. (1999) Identification of a human homologue of the *Drosophila rotated abdomen* gene (*POMT1*) encoding a putative *O*-mannosyl-transferase, and assignment to human chromosome 9q34.1. *Genomics*, **58**, 171–180.
- Endo, T. (1999) *O*-mannosyl glycans in mammals. *Biochim. Biophys. Acta*, **1473**, 237–246.
- Martin-Blanco, E. and Garcia-Bellido, A. (1996) Mutations in the *rotated abdomen* locus affect muscle development and reveal an intrinsic asymmetry in *Drosophila*. *Proc. Natl Acad. Sci. USA*, **93**, 6048–6052.
- Beltrán-Valero de Bernabé, D., Currier, S., Steinbrecher, A., Celli, J., van Beusekom, E., van der Zwaag, B., Kayserili, H., Merlini, L., Chitayat, D., Dobyns, W.B. *et al.* (2002) Mutations in the *O*-mannosyltransferase gene *POMT1* give rise to the severe neuronal migration disorder Walker–Warburg syndrome. *Am. J. Hum. Genet.*, **71**, 1033–1043.
- Cormand, B., Pihko, H., Bayes, M., Valanne, L., Santavuori, P., Talim, B., Gershoni-Baruch, R., Ahmad, A., van Bokhoven, H., Brunner, H.G. *et al.* (2001) Clinical and genetic distinction between Walker–Warburg syndrome and muscle–eye–brain disease. *Neurology*, **56**, 1059–1069.
- Dobyns, W.B., Pagon, R.A., Armstrong, D., Curry, C.J., Greenberg, F., Grix, A., Holmes, L.B., Laxova, R., Michels, V.V. and Robinow, M. (1989) Diagnostic criteria for Walker–Warburg syndrome. *Am. J. Med. Genet.*, **32**, 195–210.
- Beltrán-Valero de Bernabé, D., van Bokhoven, H., van Beusekom, E., Van den Akker, W., Kant, S., Dobyns, W.B., Cormand, B., Currier, S., Hamel, B., Talim, B. *et al.* (2003) A homozygous nonsense mutation in the Fukutin gene causes a Walker–Warburg Syndrome phenotype. *J. Med. Genet.*, in press.
- Willer, T., Amselgruber, W., Deutzmann, R. and Strahl, S. (2002) Characterization of POMT2, a novel member of the PMT protein *O*-mannosyltransferase family specifically localized to the acrosome of mammalian spermatids. *Glycobiology*, **12**, 771–783.
- Yoshida, A., Kobayashi, K., Many, H., Taniguchi, K., Kano, H., Mizuno, M., Inazu, T., Mitsuhashi, H., Takahashi, S., Takeuchi, M. *et al.* (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. *Dev. Cell*, **1**, 717–724.
- Zhang, W.L., Betel, C. and Schachter, H. (2002) Cloning and expression of a novel UDP-GlcNAc:alpha-D-mannoside beta 1,2-N-acetylglucosaminyltransferase homologous to UDP-GlcNAc:alpha-3-D-mannoside beta 1,2-N-acetylglucosaminyltransferase I. *Biochem. J.*, **361**, 153–162.
- Taniguchi, K., Kobayashi, K., Saito, K., Yamanouchi, H., Ohnuma, A., Hayashi, Y.K., Many, H., Jin, D.K., Lee, M., Parano, E. *et al.* (2003) Worldwide distribution and broader clinical spectrum of muscle–eye–brain disease. *Hum. Mol. Genet.*, **12**, 527–534.
- Takahashi, S., Sasaki, T., Many, H., Chiba, Y., Yoshida, A., Mizuno, M., Ishida, H., Ito, F., Inazu, T., Kotani, N. *et al.* (2002) A new beta 1,2-N-acetylglucosaminyltransferase that may play a role in the biosynthesis of mammalian *O*-mannosyl glycans. *Glycobiology*, **11**, 37–45.
- Kobayashi, K., Nakahori, Y., Miyake, M., Matsumura, K., Kondo-Iida, E., Nomura, Y., Segawa, M., Yoshioka, M., Saito, K., Osawa, M. *et al.* (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. *Nature*, **394**, 388–392.
- Toda, T., Kobayashi, K., Kondo-Iida, E., Sasaki, J. and Nakamura, Y. (2000) The Fukuyama congenital muscular dystrophy story. *Neuromusc. Dis.*, **10**, 153–159.
- Silan, F., Yoshioka, M., Kobayashi, K., Simsek, E., Tunc, M., Alper, M., Cam, M., Guven, A., Fukuda, Y., Kinoshita, M. *et al.* (2003) A new mutation of the fukutin gene in a non-Japanese patient. *Ann. Neurol.*, **53**, 392–396.
- Toda, T., Yoshioka, M., Nakahori, Y., Kanazawa, I., Nakamura, Y. and Nakagome, Y. (1995) Genetic identity of Fukuyama type congenital muscular dystrophy and Walker–Warburg syndrome. *Ann. Neurol.*, **37**, 99–101.
- Takeda, S., Kondo, M., Sasaki, J., Kurahasi, H., Kano, H., Arai, K., Misaki, K., Fukui, T., Kobayashi, K., Tachikawa, M. *et al.* (2003) Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. *Hum. Mol. Genet.*, **12**, 1449–1459.
- Aravind, L. and Koonin, E.V. (1999) The fukutin protein family – predicted enzymes modifying cell-surface molecules. *Curr. Biol.*, **9**, R836–R837.
- Esapa, C.T., Benson, M.A., Schroder, J.E., Martin-Rendon, E., Brockington, M., Brown, S.C., Muntoni, F., Kroger, S. and Blake, D.J. (2002) Functional requirements for fukutin-related protein in the Golgi apparatus. *Hum. Mol. Genet.*, **11**, 3319–3331.
- Brockington, M., Blake, D.J., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., Ponting, C.P., Estournet, B., Romero, N., Voit, T. *et al.* (2001) A novel glycosyltransferase is mutated in a form of congenital muscular dystrophy with secondary laminin alpha 2 deficiency and abnormal glycosylation of alpha-dystroglycan. *Am. J. Hum. Genet.*, **69**, 1198–1209.
- Brockington, M., Yuva, Y., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., Herrmann, R., Anderson, L.V.B., Bashir, R., Burgunder, J.-M. *et al.* (2001) Mutations in the fukutin-related protein gene (*FKRP*) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. *Hum. Mol. Genet.*, **10**, 2851–2859.
- Mercuri, E., Brockington, M., Straub, V., Quijano-Roy, S., Yuva, Y., Herrmann, R., Brown, S.C., Torelli, S., Dubowitz, V., Blake, D.J. *et al.* (2003) Phenotypic spectrum associated with mutations in the fukutin-related protein gene. *Ann. Neurol.*, **53**, 537–542.
- Poppe, M., Cree, L., Bourke, J., Eagle, M., Anderson, L.V.B., Birchall, D., Brockington, M., Buddles, M., Busby, M., Muntoni, F. *et al.* (2003) The phenotype of limb-girdle muscular dystrophy type 2I. *Neurology*, **60**, 1246–1251.
- Topaloglu, H., Brockington, M., Yuva, Y., Talim, B., Haliloglu, G., Blake, D., Torelli, S., Brown, S.C. and Muntoni, F. (2003) FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. *Neurology*, **60**, 988–992.
- Peyrard, M., Seroussi, E., Sandberg-Nordqvist, A.-C., Xie, Y.-G., Han, F.-Y., Fransson, I., Collins, J., Dunham, I., Kost-Alimova, M. and Imreh, S. (1999) The human *LARGE* gene from 22q12.3-q13.1 is a new distinct member of the glycosyltransferase gene family. *Proc. Natl Acad. Sci. USA*, **96**, 598–603.
- Grewal, P.K. and Hewitt, J.E. (2002) Mutation of *Large*, which encodes a putative glycosyltransferase, in an animal model of muscular dystrophy. *Biochim. Biophys. Acta*, **1573**, 216–224.
- Grewal, P.K., Holzfeind, P.J., Bittner, R.E. and Hewitt, J.E. (2001) Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. *Nat. Genet.*, **28**, 151–154.
- Lane, P.W., Beamer, T.C. and Myers, D.D. (1976) Myodystrophy, a new myopathy on chromosome 8 of the mouse. *J. Heredity*, **67**, 135–138.
- Mathews, K.D., Rapisarda, D., Bailey, H.L., Murray, J.C., Schleper, R.L. and Smith, R. (1995) Phenotypic and pathological evaluation of the myd mouse, a candidate model for facioscapulohumeral dystrophy. *J. Neuropath. Exp. Neurol.*, **54**, 601–606.

37. Rayburn, H.B. and Peterson, A.C. (1978) Naked axons in myodystrophic mice. *Brain Res.*, **146**, 380–384.
38. Holzfeind, P.J., Grewal, P.K., Reitsamer, H.A., Kechvar, J., Lassmann, H., Hoeger, H., Hewitt, J.E. and Bittner, R.E. (2002) Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large<sup>myd</sup> mouse defines a natural model for glycosylation-deficient muscle–eye–brain disorders. *Hum. Mol. Genet.*, **11**, 2673–2687.
39. Michele, D.E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R.D., Satz, J.S., Dollar, J., Nishino, I., Kelley, R.I., Somer, H. *et al.* (2002) Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies. *Nature*, **418**, 417–421.
40. Heinrichs, D.E., Monteiro, M.A., Perry, M.B. and Whitfield, C. (1998) The assembly system for the lipopolysaccharide R2 core-type of *Escherichia coli* is a hybrid of those found in *Escherichia coli* K-12 and *Salmonella enterica*. *J. Biol. Chem.*, **273**, 8849–8859.
41. Sasaki, K., Kurata-Miura, K., Ujita, M., Angata, K., Nakagawa, S., Sekine, S., Nishi, T. and Fukuda, M. (1997) Expression cloning of cDNA encoding a human  $\beta$ -1,3-*N*-acetylglucosaminyltransferase that is essential for poly-*N*-acetylglucosamine synthesis. *Proc. Natl Acad. Sci. USA*, **94**, 14294–14299.
42. Hayashi, Y.K., Ogawa, M., Tagawa, K., Noguchi, S., Ishihara, T., Nonaka, I. and Arahata, K. (2001) Selective deficiency of  $\alpha$ -dystroglycan in Fukuyama-type congenital muscular dystrophy. *Neurology*, **57**, 115–121.
43. Kano, H., Kobayashi, K., Herrmann, R., Tachikawa, M., Many, H., Nishino, I., Nonaka, I., Straub, V., Talim, B., Voit, T. *et al.* (2002) Deficiency of  $\alpha$ -dystroglycan in Muscle–Eye–Brain disease. *Biochem. Biophys. Res. Comm.*, **291**, 1283–1286.
44. Henry, M.D. and Campbell, K.P. (1999) Dystroglycan inside and out. *Curr. Opin. Cell Biol.*, **11**, 602–607.
45. Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K. and Südhof, T.C. (2001) A stoichiometric complex of neuexins and dystroglycan in brain. *J. Cell Biol.*, **154**, 435–445.
46. Cohn, R.D. and Campbell, K.P. (2000) Molecular basis of muscular dystrophies. *Muscle & Nerve*, **23**, 1456–1471.
47. Blake, D.J. and Kröger, S. (2000) The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? *TINs*, **23**, 92–99.
48. Blank, M., Blake, D.J. and Kröger, S. (2002) Molecular diversity of the dystrophin-like protein complex in the developing and adult avian retina. *Neuroscience*, **111**, 259–273.
49. Durbeej, M., Larsson, E., Ibraghimov-Beskrovnaya, O., Roberds, S.L., Campbell, K.P. and Ekblom, P. (1995) Non-muscle  $\alpha$ -dystroglycan is involved in epithelial development. *J. Cell Biol.*, **130**, 79–91.
50. Montanaro, F., Carbonetto, S., Campbell, K.P. and Lindenbaum, M. (1995) Dystroglycan expression in the wild type and mdx mouse neural retina: synaptic colocalisation with dystrophin, dystrophin-related protein but not with laminin. *J. Neurosci. Res.*, **42**, 528–538.
51. Williamson, R.A., Henry, M.D., Daniels, K.J., Hrstka, R.F., Lee, C.J., Sunada, Y., Ibraghimov-Beskrovnaya, O. and Campbell, K.P. (1997) Dystroglycan is essential for early embryonic development: disruption of Reichart's membrane in Dag1-null mice. *Hum. Mol. Genet.*, **6**, 831–841.
52. Côté, P.D., Moukhles, H., Lindenbaum, M. and Carbonetto, S. (1999) Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneuronal synapses. *Nature Genet.*, **23**, 338–342.
53. Cohn, R.D., Henry, M.D., Michele, D.E., Barresi, R., Saito, F., Moore, S.A., Flanagan, J.D., Skwarchuk, M.W., Robbins, M.E., Mendell, J.R. *et al.* (2002) Disruption of Dag1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. *Cell*, **110**, 639–648.
54. Moore, S.A., Saito, F., Chen, J., Michele, D.E., Henry, M.D., Messing, A., Cohn, R.D., Ross-Barta, S.E., Westra, S., Williamson, R.A. *et al.* (2002) Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. *Nature*, **418**, 422–425.
55. Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W. and Campbell, K.P. (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. *Nature*, **355**, 696–702.
56. Ibraghimov-Beskrovnaya, O., Milatovich, A., Ozcelik, T., Yang, B., Koepnick, K., Francke, U. and Campbell, K.P. (1993) Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue-specific isoforms and chromosomal localization. *Hum. Mol. Genet.*, **2**, 1651–1657.
57. Durbeej, M., Henry, M.D. and Campbell, K.P. (1998) Dystroglycan in development and disease. *Curr. Opin. Cell Biol.*, **10**, 594–601.
58. Ervasti, J.M. and Campbell, K.P. (1993) A role for the dystrophin–glycoprotein complex as a transmembrane linker between laminin and actin. *J. Cell Biol.*, **122**, 809–823.
59. Leschziner, A., Moukhles, H., Lindenbaum, M., Gee, S.H., Butterworth, J., Campbell, K.P. and Carbonetto, S. (2000) Neural regulation of  $\alpha$ -dystroglycan biosynthesis and glycosylation in skeletal muscle. *J. Neurochem.*, **74**, 70–80.
60. Brancaccio, A., Schulthess, T., Gesemann, M. and Engel, J. (1995) Electron microscopic evidence for a mucin-like region in chick muscle  $\alpha$ -dystroglycan. *FEBS Lett.*, **368**, 139–142.
61. Talts, J., Andac, Z., Göhring, W., Brancaccio, A. and Timpl, R. (1999) Binding of the G domains of laminin  $\alpha$ 1 and  $\alpha$ 2 chains and perlecan to heparin, sulfatides,  $\alpha$ -dystroglycan and several extracellular matrix proteins. *EMBO J.*, **18**, 863–870.
62. Brown, S.C., Fassati, A., Popplewell, L., Page, A.M., Henry, M.D., Campbell, K.P. and Dickson, G. (1999) Dystrophic phenotype induced by antibody blockade of muscle  $\alpha$ -dystroglycan–laminin interaction. *J. Cell Sci.*, **112**, 209–216.
63. Sutton-Smith, M., Morris, H.R., Grewal, P.K., Hewitt, J.E., Bittner, R.E., Goldin, E., Schiffmann, R. and Dell, A. (2002) MS screening strategies: investigating the glycomes of knockout and myodystrophic mice and leukodystrophic human brains. *Biochemical Society Symposium*, **69**, 105–115.
64. Martin, P.T. (2003) Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. *Glycobiology*, **13**, 55R–66R.
65. Smalheiser, N.R., Haslam, S.M., Sutton-Smith, M., Morris, H.R. and Dell, A. (1998) Structural analysis of sequences O-linked to mannose reveals a novel Lewis X structure in cranium (dystroglycan) purified from sheep brain. *J. Biol. Chem.*, **273**, 23698–23703.
66. Chiba, A.K., Matsumura, H., Yamada, T., Inazu, T., Shimizu, S., Kusunoki, I., Kanazawa, A., Kobata, A. and Endo, T. (1997) Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve  $\alpha$ -dystroglycan. *J. Biol. Chem.*, **272**, 2156–2162.
67. Sasaki, T., Yamada, H., Matsumura, K., Shimizu, T., Kobata, A. and Endo, T. (1998) Detection of O-mannosyl glycans in rabbit skeletal muscle  $\alpha$ -dystroglycan. *Biochim. Biophys. Acta*, **1425**, 599–606.
68. Yamada, H., Chiba, A., Endo, T., Kobata, A., Anderson, L.V.B., Hori, H., Fukata-Ori, H., Kanazawa, I., Campbell, K.P., Shimizu, T. *et al.* (1996) Characterisation of dystroglycan–laminin interaction in peripheral nerve. *J. Neurochem.*, **66**, 1518–1524.
69. Sunada, Y., Bernier, S.M., Utani, A., Yamada, Y. and Campbell, K.P. (1994) Identification of a novel mutant transcript of laminin  $\alpha$ 2-chain gene responsible for muscular dystrophy and dysmyelination in *dy*<sup>2J</sup> mice. *Hum. Mol. Genet.*, **4**, 1055–1061.
70. Xu, H., Wu, X.-R., Wewer, U.M. and Engvall, E. (1994) Murine muscular dystrophy caused by a mutation in the laminin  $\alpha$ 2 (*Lama2*) gene. *Nature Genet.*, **8**, 297–301.
71. Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tomé, F.M.S., Schwartz, K., Fardeau, M., Tryggvason, K. *et al.* (1995) Mutations in the laminin  $\alpha$ 2-chain (*LAMA2*) cause merosin-deficient congenital muscular dystrophy. *Nature Genet.*, **11**, 216–218.
72. Henion, T.R., Qu, Q. and Smith, F.I. (2003) Expression of dystroglycan, fukutin and POMGnT1 during mouse cerebellar development. *Mol. Brain Res.*, **112**, 177–181.